Immunotherapy takes advantage of the immune system to prevent, control, and eliminate neoplastic cells. The research in the field has already led to major breakthroughs to treat cancer. In this work, we describe a platform that integrates in vitro bioassays to test the immune response and direct antitumor effects for the preclinical discovery of anticancer candidates. The platform relies on the use of dendritic cells that are professional antigen-presenting cells (APC) able to activate T cells and trigger a primary adaptive immune response. The experimental procedure is based on two phenotypic assays for the selection of chemical leads by both a panel of nine tumor cell lines and growth factor-dependent immature mouse dendritic cells (D1). The positive hits are then validated by a secondary test on human monocyte-derived dendritic cells (MoDCs). The aim of this approach is the selection of potential immunotherapeutic small molecules from natural extracts or chemical libraries.

A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity / Gallo, Carmela; Barra, Giusi; Saponaro, Marisa; Manzo, Emiliano; Fioretto, Laura; Ziaco, Marcello; Nuzzo, Genoveffa; D'Ippolito, Giuliana; De Palma, Raffaele; Fontana, Angelo. - In: MARINE DRUGS. - ISSN 1660-3397. - 18:12(2020), p. 604. [10.3390/md18120604]

A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity

Gallo, Carmela
;
Manzo, Emiliano;Fioretto, Laura;Ziaco, Marcello;Fontana, Angelo
2020

Abstract

Immunotherapy takes advantage of the immune system to prevent, control, and eliminate neoplastic cells. The research in the field has already led to major breakthroughs to treat cancer. In this work, we describe a platform that integrates in vitro bioassays to test the immune response and direct antitumor effects for the preclinical discovery of anticancer candidates. The platform relies on the use of dendritic cells that are professional antigen-presenting cells (APC) able to activate T cells and trigger a primary adaptive immune response. The experimental procedure is based on two phenotypic assays for the selection of chemical leads by both a panel of nine tumor cell lines and growth factor-dependent immature mouse dendritic cells (D1). The positive hits are then validated by a secondary test on human monocyte-derived dendritic cells (MoDCs). The aim of this approach is the selection of potential immunotherapeutic small molecules from natural extracts or chemical libraries.
2020
A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity / Gallo, Carmela; Barra, Giusi; Saponaro, Marisa; Manzo, Emiliano; Fioretto, Laura; Ziaco, Marcello; Nuzzo, Genoveffa; D'Ippolito, Giuliana; De Palma, Raffaele; Fontana, Angelo. - In: MARINE DRUGS. - ISSN 1660-3397. - 18:12(2020), p. 604. [10.3390/md18120604]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/902329
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact